Neurotech International Ltd (NTI) - Total Assets
Based on the latest financial reports, Neurotech International Ltd (NTI) holds total assets worth AU$6.81 Million AUD (≈ $4.82 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See NTI net assets for net asset value and shareholders' equity analysis.
Neurotech International Ltd - Total Assets Trend (2015–2025)
This chart illustrates how Neurotech International Ltd's total assets have evolved over time, based on quarterly financial data.
Neurotech International Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Neurotech International Ltd's total assets of AU$6.81 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 93.5% |
| Accounts Receivable | AU$88.70K | 2.7% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Neurotech International Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Neurotech International Ltd stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neurotech International Ltd's current assets represent 100.0% of total assets in 2025, an increase from 64.5% in 2015.
- Cash Position: Cash and equivalents constituted 93.5% of total assets in 2025, up from 57.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 23.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 2.7% of total assets.
Neurotech International Ltd Competitors by Total Assets
Key competitors of Neurotech International Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Neurotech International Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.30 | 9.25 | 6.30 |
| Quick Ratio | 7.30 | 9.25 | 6.30 |
| Cash Ratio | 0.00 | 0.00 | 5.64 |
| Working Capital | AU$5.88 Million | AU$5.74 Million | AU$1.90 Million |
Neurotech International Ltd - Advanced Valuation Insights
This section examines the relationship between Neurotech International Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.54 |
| Latest Market Cap to Assets Ratio | 3.40 |
| Asset Growth Rate (YoY) | -73.5% |
| Total Assets | AU$3.24 Million |
| Market Capitalization | $11.01 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Neurotech International Ltd's assets at a significant premium (3.40x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Neurotech International Ltd's assets decreased by 73.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Neurotech International Ltd (2015–2025)
The table below shows the annual total assets of Neurotech International Ltd from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$3.24 Million ≈ $2.29 Million |
-73.47% |
| 2024-06-30 | AU$12.21 Million ≈ $8.64 Million |
+130.06% |
| 2023-06-30 | AU$5.31 Million ≈ $3.76 Million |
+162.43% |
| 2022-06-30 | AU$2.02 Million ≈ $1.43 Million |
-59.59% |
| 2021-06-30 | AU$5.01 Million ≈ $3.54 Million |
+6095.02% |
| 2020-06-30 | AU$80.81K ≈ $57.17K |
-87.62% |
| 2019-06-30 | AU$652.75K ≈ $461.86K |
-85.83% |
| 2018-06-30 | AU$4.61 Million ≈ $3.26 Million |
-6.98% |
| 2017-06-30 | AU$4.95 Million ≈ $3.50 Million |
-67.79% |
| 2016-06-30 | AU$15.37 Million ≈ $10.88 Million |
+368.28% |
| 2015-12-31 | AU$3.28 Million ≈ $2.32 Million |
-- |
About Neurotech International Ltd
Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxati… Read more